SG145744A1 - Process for the preparation of 4-amino-3- quinolinecarbonitriles - Google Patents

Process for the preparation of 4-amino-3- quinolinecarbonitriles

Info

Publication number
SG145744A1
SG145744A1 SG200806052-7A SG2008060527A SG145744A1 SG 145744 A1 SG145744 A1 SG 145744A1 SG 2008060527 A SG2008060527 A SG 2008060527A SG 145744 A1 SG145744 A1 SG 145744A1
Authority
SG
Singapore
Prior art keywords
preparation
amino
quinolinecarbonitriles
discloses
quinolinecarbonitrile
Prior art date
Application number
SG200806052-7A
Other languages
English (en)
Inventor
Karen Wiggins Sutherland
Gregg Brian Feigelson
Diane Harris Boschelli
David Michael Blum
Henry Lee Strong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34215972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG145744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG145744A1 publication Critical patent/SG145744A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
SG200806052-7A 2003-08-19 2004-08-13 Process for the preparation of 4-amino-3- quinolinecarbonitriles SG145744A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49619103P 2003-08-19 2003-08-19

Publications (1)

Publication Number Publication Date
SG145744A1 true SG145744A1 (en) 2008-09-29

Family

ID=34215972

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200806052-7A SG145744A1 (en) 2003-08-19 2004-08-13 Process for the preparation of 4-amino-3- quinolinecarbonitriles

Country Status (25)

Country Link
US (2) US7297795B2 (fr)
EP (1) EP1660453A2 (fr)
JP (1) JP2007502819A (fr)
KR (1) KR20060066733A (fr)
CN (1) CN1835923A (fr)
AR (1) AR045277A1 (fr)
AU (1) AU2004267061A1 (fr)
BR (1) BRPI0413667A (fr)
CA (1) CA2535385A1 (fr)
CO (1) CO5670369A2 (fr)
CR (1) CR8226A (fr)
EC (1) ECSP066384A (fr)
GT (1) GT200400165A (fr)
IL (1) IL173456A0 (fr)
MX (1) MXPA06001590A (fr)
MY (1) MY140542A (fr)
NO (1) NO20060539L (fr)
PA (1) PA8609301A1 (fr)
PE (1) PE20050344A1 (fr)
RU (1) RU2345069C2 (fr)
SA (1) SA04250258B1 (fr)
SG (1) SG145744A1 (fr)
SV (1) SV2005001855A (fr)
TW (1) TW200517378A (fr)
WO (1) WO2005019201A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479561B2 (en) * 2004-08-16 2009-01-20 Wyeth 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1888529A2 (fr) * 2005-05-18 2008-02-20 Wyeth Inhibiteurs 3-cyanoquinoline de la tpl2 kinase et procedes de production et d'utilisation associes
WO2006127203A2 (fr) * 2005-05-25 2006-11-30 Wyeth Procedes de synthese de derives de 6-alkylaminoquinoline
CN101203494A (zh) * 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
CA2608394A1 (fr) * 2005-05-25 2006-11-30 Wyeth Procedes de preparation de 3-cyano-quinoleines et intermediaires concus au moyen de ceux-ci
AU2006266045A1 (en) * 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
EP1942937A1 (fr) 2005-11-04 2008-07-16 Wyeth Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
CN101378758A (zh) * 2006-02-08 2009-03-04 惠氏公司 经由钯介导的偶联反应制备7-烯基-3氰基喹啉
CN101195578B (zh) * 2006-12-08 2012-04-25 上海睿智化学研究有限公司 1-(卤烷氧基)-2-烷氧基-5-硝基苯类化合物的合成方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
CN102470109A (zh) 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
CN101792416B (zh) * 2010-01-15 2011-10-05 南京医科大学 一种博舒替尼的制备工艺
MX342164B (es) * 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
WO2013187967A1 (fr) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensibilisation de cellules cancéreuses en vue de la détérioration de l'adn par l'inhibition de kinases essentielles pour la régulation de la surveillance de la détérioration de l'adn
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
IN2014CH00840A (fr) 2014-02-20 2015-09-18 Apotex Inc
CN104876865A (zh) * 2014-02-27 2015-09-02 南京正荣医药化学有限公司 一种博舒替尼的制备工艺
NZ738538A (en) 2015-07-06 2019-06-28 Gilead Sciences Inc 6-amino-quinoline-3-carbonitrils as cot modulators
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CA3029457A1 (fr) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines utilisees comme modulateurs de cot et leurs methodes d'utilisation
WO2019076316A1 (fr) * 2017-10-18 2019-04-25 江苏恒瑞医药股份有限公司 Procédé de préparation d'inhibiteur de tyrosine kinase et d'intermédiaire de celui-ci
CN108084085B (zh) * 2017-12-28 2019-11-26 山东铂源药业有限公司 一种n-(3-氯-4-(2-吡啶甲氧基)苯基)-2-氰基乙酰胺的制备方法
WO2019186429A1 (fr) * 2018-03-30 2019-10-03 Sun Pharmaceutical Industries Limited Procédé de préparation de bosutinib
CN109180578B (zh) * 2018-10-19 2020-06-26 山东创新药物研发有限公司 一种博舒替尼的制备方法
CN111646939A (zh) * 2019-03-04 2020-09-11 鲁南制药集团股份有限公司 一种博舒替尼的制备方法
CN111646955B (zh) * 2019-03-04 2024-05-24 鲁南制药集团股份有限公司 一种制备博舒替尼中间体的方法
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CA3175541A1 (fr) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile un compose inhibiteur de cot
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція

Also Published As

Publication number Publication date
US7297795B2 (en) 2007-11-20
SV2005001855A (es) 2005-11-04
EP1660453A2 (fr) 2006-05-31
BRPI0413667A (pt) 2006-10-24
NO20060539L (no) 2006-02-13
SA04250258B1 (ar) 2009-01-07
WO2005019201A3 (fr) 2005-08-04
CN1835923A (zh) 2006-09-20
AR045277A1 (es) 2005-10-19
CO5670369A2 (es) 2006-08-31
RU2006108524A (ru) 2007-09-27
GT200400165A (es) 2005-04-12
AU2004267061A1 (en) 2005-03-03
WO2005019201A2 (fr) 2005-03-03
ECSP066384A (es) 2006-08-30
US20080033175A1 (en) 2008-02-07
IL173456A0 (en) 2006-06-11
US20050043537A1 (en) 2005-02-24
MXPA06001590A (es) 2006-05-19
JP2007502819A (ja) 2007-02-15
KR20060066733A (ko) 2006-06-16
CR8226A (es) 2008-08-21
PE20050344A1 (es) 2005-06-19
RU2345069C2 (ru) 2009-01-27
MY140542A (en) 2009-12-31
PA8609301A1 (es) 2005-03-03
CA2535385A1 (fr) 2005-03-03
TW200517378A (en) 2005-06-01

Similar Documents

Publication Publication Date Title
SG145744A1 (en) Process for the preparation of 4-amino-3- quinolinecarbonitriles
AU2002348135A1 (en) Methods for the treatment of addiction
AP2004002981A0 (en) Method for the preparation of hexahydro-furo [2,3-B]furan-3-o1.
AU2003237305A1 (en) Process of preparation of olanzapine form i
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
MXPA03008205A (es) Procedimiento para la preparacion de compuestos de imidazol.
EG23203A (en) Technical process for the manufacture of tropenol.
HUP0402475A3 (en) Process for the preparation of [1,4,5]-oxadiazepine derivatives
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
IL174415A0 (en) Process for preparing an azabicyclo[3.1.0] hexane compound
EP1436279B8 (fr) Composes chimiques
MXPA02003042A (es) Proceso para prevenir formacion de incrustaciones.
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
AU2002335992A1 (en) Process for the production of ascopyrone p
IL176153A0 (en) Method for the production of 2,3-cis-substituted 2-aryl propenals
AU2003269482A1 (en) Process for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde
AU2003252509A1 (en) NOVEL PROCESS FOR PRODUCING IMIDAZO(1,2-b)PYRIDAZINE DERIVATIVE
EG23229A (en) Process for the production of olefins.
WO2004065390A8 (fr) Procede et intermediaires pour la preparation d'olanzapine
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
AU2002352014A1 (en) Method for the production of organodiphosphonites
HU0203956D0 (en) Process for the preparation of linear or branched 1,4-cis polybutadiene
EG23233A (en) Method for the production of tyres.